Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Marine lipids, particularly omega-3 polyunsaturated fatty acids (PUFAs) such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been investigated for their potential to support cancer patients by reducing treatment side effects. Several preclinical and clinical studies suggest that marine lipids may help mitigate cancer-related cachexia (muscle wasting), chemotherapy-induced inflammation, and some gastrointestinal side effects. For example, a number of randomized controlled trials have reported that supplementation with EPA can help stabilize or improve body weight and lean body mass in patients with advanced cancer, potentially counteracting the muscle wasting commonly observed during cancer progression and treatment (Murphy et al., 2011). Additionally, omega-3 fatty acids possess anti-inflammatory properties, which may help reduce the severity of inflammation-based side effects from chemotherapy and radiation therapy. Some studies have also indicated improved quality of life and reduced fatigue in cancer patients taking marine lipid supplements. However, results are not universally positive; some trials have shown minimal or no benefit, and optimal dosing, timing, and patient selection remain under investigation (Weaver et al., 2018). In summary, while marine lipids are not a substitute for standard cancer treatments, moderate scientific evidence supports their adjunctive use in reducing certain treatment side effects, particularly those related to inflammation and cachexia. Further research is needed to refine recommendations and confirm benefits across broader cancer populations.

More about marine lipid
More about Cancer Treatment (reducing side effects)

Other ingredients used for Cancer Treatment (reducing side effects)

Other health conditions supported by marine lipid

Products containing marine lipid